# Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Source: https://onco.cc/trials/nct06635824/  
OnCo record `nct06635824` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Acasunlimab in non-small-cell lung cancer, active and no longer recruiting.

## Summary

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) is a phase 3 interventional study registered as NCT06635824, led by Genmab, and active but no longer recruiting on the registry. Official title: A Prospective, Open-Label, Randomised, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06). Planned enrolment is 191 participants (actual). The study started in 2024-11-25 and primary completion is expected in 2027-07-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: ABBIL1TY NSCLC-06
- Tags: ctgov-ingest
- Registry id: NCT06635824
- Phase: 3
- Setting: A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
- Sponsor: Genmab
- Enrolled: 191

## Sources

- ClinicalTrials.gov NCT06635824: https://clinicaltrials.gov/study/NCT06635824

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Acasunlimab](https://onco.cc/drugs/acasunlimab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct06635824.json